Recent 8-K filings for BTCY
Highest-materiality recent filing
Biotricity receives Nasdaq delisting notice; trading suspended August 5, 2024
- Nasdaq Hearings Panel determined to delist Biotricity's common stock; trading suspended at open Aug 5, 2024.
- Non-compliance with minimum $35M market value of listed securities (MVLS) rule; compliance deadline extended to July 29, 2024.
-
Biotricity exchanges common, options, warrants for Series C preferred with 40 votes per share
14.14M common shares, 3.99M options, and 1.44M warrants exchanged for 1.96M Series C shares at a 10:1 ratio.
-
Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M
Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.
-
Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M
Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.
-
Biotricity Q3 FY25 revenue $3.6M (+21.7% YoY); net loss down 56.7% to $1.32M
Gross margin improved to 76.4% from 72.9% YoY; recurring tech fees 94% of revenue at 81.4% gross profit.
-
Biotricity Q2 FY2025 revenue up 13% YoY to $3.3M; net loss down 57% to $1.65M
Revenue $3.3M (+13% YoY); gross margin improved to 75.3% from 69.1%.
-
Biotricity shareholders reject proposal to issue $6.6M in common stock upon Series B conversion
Annual meeting held August 15, 2024; all four director nominees elected.
-
Biotricity receives Nasdaq delisting notice; trading suspended August 5, 2024
Nasdaq Hearings Panel determined to delist Biotricity's common stock; trading suspended at open Aug 5, 2024.
-
Biotricity receives Nasdaq bid price deficiency notice; 180-day cure period to Jan 22, 2025
Closing bid price below $1.00 for 30 consecutive business days triggers Nasdaq Listing Rule 5550(a)(2) deficiency.
-
Biotricity closes second tranche of Series B Preferred Stock private placement for $500,000
Second closing of 55 shares of Series B Convertible Preferred Stock at $9,090.91/share for gross proceeds of $500,000.
-
Biotricity shareholders approve non-public securities issuance at special meeting
Special meeting held July 12, 2024 approved issuance of securities in one or more non-public offerings.
-
Biotricity raises $500K in Series B Preferred placement; up to $1.5M additional
Issued 55 Series B Preferred shares at $9,090.91 each for gross proceeds of $500,000 on June 21, 2024.
-
Biotricity issues 8.95M common shares on conversion of Series A Preferred
Issued 8,952,172 common shares to investors upon conversion of 6,104 Series A Preferred shares plus accrued dividends and fees.
-
Biotricity amends ATM offering to raise up to $2.68M in common stock
Amendment to March 2022 ATM agreement with H.C. Wainwright for up to $2,684,644 of common stock.
-
Biotricity raises $645,455 in third closing of Series B Preferred; total $2M private placement
Issued 71 shares of Series B Convertible Preferred to Ionic Ventures for $645,455 on May 15, 2024.
-
Biotricity faces Nasdaq delisting for missing annual meeting; closes $354k private placement
Nasdaq notified Biotricity on May 1, 2024 of non-compliance with annual meeting rule; additional delisting basis.
-
Nasdaq panel grants Biotricity continued listing subject to milestones by July 29, 2024
Panel granted listing continuation after hearing on April 9, 2024.
-
Biotricity amends Series B Preferred Stock to remove voting rights; approved by holder
Amended Certificate of Designations removes voting rights of Series B Preferred Stock (non-voting except as required by law).
-
Gross proceeds of $1M from sale of 110 Series B Convertible Preferred shares at $9,090.91 each.
-
Received delisting letter on Jan 30, 2024, for not regaining compliance with $35M MVLS requirement by Jan 29, 2024.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event other_material